journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/30005764/correction
#1
(no author information available yet)
No abstract text is available yet for this article.
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005763/a-multigene-test-could-cost-effectively-help-extend-life-expectancy-for-women-at-risk-of-hereditary-breast-cancer-reply-to-letter-to-the-editor-by-petelin-et-al
#2
LETTER
Yonghong Li, James J Devlin
No abstract text is available yet for this article.
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005762/heterogeneity-and-uncertainties-specific-to-genome-based-health-technological-assessments
#3
LETTER
Lara Petelin, Danny Liew, Gillian Mitchell, Paul A James, Alison H Trainer
No abstract text is available yet for this article.
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005761/economic-burden-of-cardiovascular-disease-in-type-2-diabetes-a-systematic-review
#4
REVIEW
Thomas R Einarson, Annabel Acs, Craig Ludwig, Ulrik H Panton
BACKGROUND: Cardiovascular diseases (CVDs) constitute major comorbidities in type 2 diabetes mellitus (T2DM), contributing substantially to treatment costs for T2DM. An updated overview of the economic burden of CVD in T2DM has not been presented to date. OBJECTIVE: To systematically review published articles describing the costs associated with treating CVD in people with T2DM. METHODS: Two reviewers searched MEDLINE, Embase, and abstracts from scientific meetings to identify original research published between 2007 and 2017, with no restrictions on language...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005760/medical-treatments-for-acromegaly-a-systematic-review-and-network-meta-analysis
#5
REVIEW
Letícia P Leonart, Vinicius L Ferreira, Fernanda S Tonin, Fernando Fernandez-Llimos, Roberto Pontarolo
BACKGROUND: Acromegaly results from the hypersecretion of growth hormone. Because of the low incidence rates of this disease worldwide, few clinical trials evaluating drug treatments have been conducted. OBJECTIVES: To conduct the first network meta-analysis simultaneously comparing all available drugs used in acromegaly treatment so as to provide more robust evidence in this field. METHODS: A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Collaboration recommendations (PROSPERO database under the registration number CRD42017059880)...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005759/critical-analysis-of-markov-models-used-for-the-economic-evaluation-of-colorectal-cancer-screening-a-systematic-review
#6
REVIEW
Nicolas Silva-Illanes, Manuel Espinoza
BACKGROUND: The economic evaluation of colorectal cancer screening is challenging because of the need to model the underlying unobservable natural history of the disease. OBJECTIVES: To describe the available Markov models and to critically analyze their main structural assumptions. METHODS: A systematic search was performed in eight relevant databases (MEDLINE, Embase, Econlit, National Health Service Economic Evaluation Database, Health Economic Evaluations Database, Health Technology Assessment database, Cost-Effective Analysis Registry, and European Network of Health Economics Evaluation Databases), identifying 34 models that met the inclusion criteria...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005758/uncertainty-and-the-undervaluation-of-services-for-severe-health-states-in-cost-utility-analyses
#7
Jeff Richardson, Angelo Iezzi, Aimee Maxwell
OBJECTIVES: To test the hypothesis that the "severity effect"-the preference for more than utility-maximizing expenditure on severe health states-may be the result of, or exacerbated by, the uncertainty associated with the chance of contracting the illness that causes the severe health state. METHODS: Survey respondents were asked to imagine that they will contract one of two illnesses and asked to allocate a budget between two insurance policies, each of which provides services for the treatment of one of the illnesses...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005757/what-characteristics-of-nursing-homes-are-most-valued-by-consumers-a-discrete-choice-experiment-with-residents-and-family-members
#8
Rachel Milte, Julie Ratcliffe, Gang Chen, Maria Crotty
OBJECTIVES: To generate a scoring algorithm weighted on the preferences of consumers for assessing the quality of care in nursing homes (i.e., aged care homes or institutions) in six key domains. METHODS: A discrete choice experiment was undertaken with residents of nursing homes (n = 126) or family member proxies (n = 416) in cases where severe cognitive impairment precluded resident participation. Analysis was undertaken using conditional and mixed logit regression models to determine preferences for potential attributes...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005756/informing-a-priori-sample-size-estimation-in-qualitative-concept-elicitation-interview-studies-for-clinical-outcome-assessment-instrument-development
#9
Diane M Turner-Bowker, Roger E Lamoureux, Jonathan Stokes, Leighann Litcher-Kelly, Nina Galipeau, Andrew Yaworsky, Jeffrey Solomon, Alan L Shields
OBJECTIVE: Evidence-based recommendations for the a priori estimation of sample size are needed for qualitative concept elicitation (CE) interview studies in clinical outcome assessment (COA) instrument development. Saturation is described as the point at which no new data is expected to emerge from the conduct of additional qualitative interviews. STUDY DESIGN: A retrospective evaluation of 26 CE interview studies conducted with patients between 2006 and 2013 was completed to assess the point at which saturation of concept was achieved in each study...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005755/can-social-care-needs-and-well-being-be-explained-by-the-eq-5d-analysis-of-the-health-survey-for-england
#10
Jeshika Singh, Subhash Pokhrel, Louise Longworth
BACKGROUND: The recent shift to an integrated approach to health and social care aims to provide cohesive support to those who are in need of care, but raises a challenge for resource allocation decision making, in particular for comparison of diverse benefits from different types of care across the two sectors. OBJECTIVE: To investigate the relationship of social care needs and well-being with a generic health status measure using multivariate regression. METHODS: We empirically compared responses to health and well-being measures and social care needs from a cross-sectional data set of the general population (the Health Survey for England)...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005754/value-of-external-data-in-the-extrapolation-of-survival-data-a-study-using-the-njr-data-set
#11
Mark Pennington, Richard Grieve, Jan Van der Meulen, Neil Hawkins
BACKGROUND: Extrapolation of time-to-event data can be a critical component of cost-effectiveness analysis. OBJECTIVES: To contrast the value of external data on treatment effects as a selection aid in model fitting to the clinical data or for the direct extrapolation of survival. METHODS: We assume the existence of external summary data on both treatment and control and consider two scenarios: availability of external individual patient data (IPD) on the control only and an absence of external IPD...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005753/time-to-entry-for-new-cancer-medicines-from-european-union-wide-marketing-authorization-to-patient-access-in-belgium-estonia-scotland-and-sweden
#12
Alessandra Ferrario
OBJECTIVES: First, to quantify the median time from European Union (EU)-wide approval to first use (launch) for a sample of cancer medicines and number of launches in Belgium, Estonia, Scotland, and Sweden as of June 2015. Second, to assess whether longer times to launch or lack of launches affected medicines with high or low expected additional clinical benefit. Third, to identify possible determinants of the probability of a cancer medicine to be launched. METHODS: Correlation between time to launch and a set of variables hypothesized to affect launch was tested using a complementary log-log model for a sample of 46 cancer medicines that obtained EU-wide marketing authorization between 2000 and 2014...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005752/personalized-mammography-screening-and-screening-adherence-a-simulation-and-economic-evaluation
#13
Matthias Arnold, Anne S Quante
OBJECTIVE: Personalized breast cancer screening has so far been economically evaluated under the assumption of full screening adherence. This is the first study to evaluate the effects of nonadherence on the evaluation and selection of personalized screening strategies. METHODS: Different adherence scenarios were established on the basis of findings from the literature. A Markov microsimulation model was adapted to evaluate the effects of these adherence scenarios on three different personalized strategies...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005751/long-term-health-and-economic-value-of-improved-mobility-among-older-adults-in-the-united-states
#14
Mina Kabiri, Michelle Brauer, Jason Shafrin, Jeff Sullivan, Thomas M Gill, Dana P Goldman
BACKGROUND: Mobility impairments have substantial physical and mental health consequences, resulting in diminished quality of life. Most studies on the health economic consequences of mobility limitations focus on short-term implications. OBJECTIVES: To examine the long-term value of improving mobility in older adults. METHODS: Our six-step approach used clinical trial data to calibrate mobility improvements and estimate health economic outcomes using a microsimulation model...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005750/economic-evaluation-of-the-hepatitis-c-virus-treatment-extension-to-early-stage-fibrosis-patients-evidence-from-the-piter-real-world-cohort
#15
Matteo Ruggeri, Silvia Coretti, Federica Romano, Loreta A Kondili, Stefano Vella, Americo Cicchetti
OBJECTIVES: To conduct a cost-effectiveness analysis of two planning strategies of the second-generation direct-acting antiviral interferon-free regimens for the treatment of chronic hepatitis C virus infection. METHODS: A lifetime multicohort model comprised 8125 real-life patients enrolled in the PITER (Italian platform for the study of viral hepatitis) registry, implemented by the ISS (Istituto Superiore di Sanità). Two treatment planning strategies were compared: 1) policy 1-treat all patients regardless of the stage of fibrosis (F0-F4) with second-generation direct-acting antivirals and 2) policy 2-treat patients at F3/F4 stage and those who are prioritized by the scientific guidelines first, and the remaining patients when they reach the F3 stage...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005749/cost-effectiveness-analysis-in-telehealth-a-comparison-between-home-telemonitoring-nurse-telephone-support-and-usual-care-in-chronic-heart-failure-management
#16
Andrija S Grustam, Johan L Severens, Daniele De Massari, Nasuh Buyukkaramikli, Ron Koymans, Hubertus J M Vrijhoef
OBJECTIVES: To assess the cost effectiveness of home telemonitoring (HTM) and nurse telephone support (NTS) compared with usual care (UC) in the management of patients with chronic heart failure, from a third-party payer's perspective. METHODS: We developed a Markov model with a 20-year time horizon to analyze the cost effectiveness using the original study (Trans-European Network-Home-Care Management System) and various data sources. A probabilistic sensitivity analysis was performed to assess the decision uncertainty in our model...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005748/effect-of-level-overlap-and-color-coding-on-attribute-non-attendance-in-discrete-choice-experiments
#17
Marcel F Jonker, Bas Donkers, Esther W de Bekker-Grob, Elly A Stolk
OBJECTIVE: The aim of this study was to test the hypothesis that level overlap and color coding can mitigate or even preclude the occurrence of attribute nonattendance in discrete choice experiments. METHODS: A randomized controlled experiment with five experimental study arms was designed to investigate the independent and combined impact of level overlap and color coding on respondents' attribute nonattendance. The systematic differences between the study arms allowed for a direct comparison of observed dropout rates and estimates of the average number of attributes attended to by respondents, which were obtained by using augmented mixed logit models that explicitly incorporated attribute non-attendance...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005747/best-methods-of-communicating-clinical-trial-data-to-improve-understanding-of-treatments-for-patients-with-multiple-sclerosis
#18
Gurpreet K Reen, Eli Silber, Dawn W Langdon
BACKGROUND: Patients' understanding of treatment risks and benefits is a prerequisite for shared decision making. Yet, patients with multiple sclerosis (MS) do not accurately understand treatment information provided in regular clinical consultations. OBJECTIVES: To identify the best methods of communicating clinical trial data to improve the understanding of treatments among patients with MS and to also examine the relationship between patients' understanding with decisional conflict, individual traits, and MS symptoms...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/30005746/use-and-misuse-of-cost-effectiveness-analysis-thresholds-in-low-and-middle-income-countries-trends-in-cost-per-daly-studies
#19
Ashley A Leech, David D Kim, Joshua T Cohen, Peter J Neumann
OBJECTIVES: To determine what thresholds are most often cited in the cost-effectiveness literature for low- and middle-income countries (LMICs), given various recommendations proposed and used in the literature to date, and thereafter to assess whether studies appropriately justified their use of threshold values. METHODS: We reviewed the contents of the Tufts Medical Center Global Health Cost-Effectiveness Analysis Registry, a repository of all English language cost-per-disability-adjusted life-year averted studies indexed in PubMed...
July 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29909881/development-of-methods-for-the-mapping-of-utilities-using-mixture-models-mapping-the-aqlq-s-to-the-eq-5d-5l-and-the-hui3-in-patients-with-asthma
#20
Laura A Gray, Mónica Hernández Alava, Allan J Wailoo
BACKGROUND: Studies have shown that methods based on mixture models work well when mapping clinical to preference-based methods. OBJECTIVES: To develop these methods in different ways and to compare performance in a case study. METHODS: Data from 856 patients with asthma allowed mapping between the Asthma Quality of Life Questionnaire and both the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) and the health utilities index mark 3 (HUI3)...
June 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"